Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.
Biopharma and med-tech companies raising money in public or private financings, including: Abram, Bicara, Breezebio, Octapharma, Respiree, Trinity, Zura.
At Biocom’s Global Partnering and Investor Conference, venture capitalists (VCs) on multiple panels offered their thoughts on the state of venture investing and offered advice for startups interested in securing funding. Sentiment for early stage investment was somewhat mixed, but trended negative as VCs acknowledged that it’s a tough environment in which to raise capital.
Breezebio Inc., formerly known as Genedit Inc., has closed $60 million in series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s Nanogalaxy delivery platform.
Biopharma and med-tech companies raising money in public or private financings, including: Abbott, Allurion, Alveus, Brainomix, Centauri, Exact Sciences, Salspera, Slate, Tandem Diabetes.
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders.
Innovacell Inc. launched a ¥14.16 billion (US$91.2 million) stock sale on the Tokyo Stock Exchange Feb. 24, ending a near two-year lull of biotech listings in Japan while signaling a dynamic year ahead for cell-based therapeutics.
Ascletis Pharma Inc. raised HK$843.53 million (US107.93 million) in a placement on the Hong Kong Stock Exchange to advance its lead program, ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that can be dosed once monthly subcutaneously and once daily orally for treating obesity.
RSS
